The Weekly Recap 5/9/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

 In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $45M in new funds, receive regulatory clearance, announce product launches, and much more on the road to LSI Asia ’25 in Singapore (June 10–13).

AliveCor

Launched the KardiaMobile® 6L Max, an AI-powered personal ECG system with the widest range of arrhythmia detection available over the counter. The company also introduced KardiaAlert, a new feature for KardiaCare subscribers that monitors ECG changes over time and alerts patients to potential risks, empowering earlier interventions and more informed care conversations.

Avvio Medical

Treated the first patients in its clinical trial of the Enhanced Lithotripsy System (ELS), a minimally invasive kidney stone therapy designed for outpatient settings. With IDE approval from the FDA, Avvio aims to shift treatment out of the OR and into ASCs and cystoscopy suites, eliminating the need for general anesthesia, fluoroscopy, or expensive capital equipment.

Cerulean Scientific

Shared results from Aim 1 of its NIH Phase 1 grant with strong preclinical results showing that TLP-coated vascular grafts resisted thrombus formation over 90 days of flow-conditioning. The tethered liquid perfluorocarbon coating maintained its omniphobic properties under physiologic shear, marking a key milestone in redefining care standards for peripheral artery disease.

Cosm Medical

Closed the first tranche of its Seed Extension round to accelerate commercialization of its AI-powered, personalized, 3D-printed pelvic health solutions. The funding supports expansion following FDA clearance and fuels upcoming clinical presentations at IUGA and key events across the U.S. women’s health landscape.

Coramaze Technologies

Appointed medtech industry veteran Rob ten Hoedt as Chair of the Board to guide the global strategy and clinical advancement of its Tripair™ system for tricuspid regurgitation. The appointment, following a successful executive search by Coulter Partners and MTIP, marks a pivotal step as Coramaze transitions from feasibility studies toward pivotal trials and commercialization.

Endospan

Reported positive 30-day results from the TRIOMPHE IDE clinical study of the NEXUS® Aortic Arch Stent-Graft System, with 0% operative mortality and no Type Ia, Type Ib, or Type III endoleaks. The data, presented at AATS 2025, support NEXUS as a promising alternative to open surgery for high-risk patients with complex aortic arch pathologies.

Field Orthopaedics

Received TGA ARTG inclusion for the Extremity All Suture System (EASS) Griplasty™ Systems, a single-incision, all-suture implant developed to treat advanced-stage thumb carpometacarpal osteoarthritis. The regulatory milestone supports broader access to innovative surgical options for treating one of the most common degenerative conditions of the hand.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-5925-lsi-alumni-achievements-driving-medtech-and-healthtech-forward

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more